All In Biotech

Drug Trial Radar · NCT02979522

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

An Open-Label Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

59

Actual

Start

Sep 6, 2017

Primary completion

May 5, 2020

Study completion Sep 24, 2029

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Dec 1, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen, doxorubicin (Adriamycin), vinblastine, and dacarbazine, in pediatric participants with advanced stage newly diagnosed classical CD30+ Hodgkin Lymphoma (HL).

Conditions

  • Hodgkin Disease

Interventions

  • Brentuximab vedotinDrug

    Brentuximab vedotin infusion

  • DoxorubicinDrug

    Doxorubicin infusion

  • VinblastineDrug

    Vinblastine infusion

  • DacarbazineDrug

    Dacarbazine infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Recommended Dose of Brentuximab Vedotin in Combination With Doxorubicin, Vinblastine, and Dacarbazine in a Pediatric PopulationTime frame: From the first dose (Cycle 1) up to Day 56 (Cycle length=28 days)
  2. Phase 1: Percentage of Participants Who Experienced Adverse Events (AEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol TherapyTime frame: From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)
  3. Phase 1: Percentage of Participants Who Experienced Serious Adverse Events (SAEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol TherapyTime frame: From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)
  4. Phase 2: Percentage of Participants Who Achieved a Complete Remission (CR) Per Independent Review Facility (IRF) Assessment Per International Working Group (IWG) Criteria at End of Treatment (EOT) VisitTime frame: At end of treatment (EOT) visit 30 days after the last dose of study drug (at Month 7)
  5. Phase 2: Percentage of Participants Whose Disease Was Positron Emission Tomography (PET) Negative After 2 Cycles of Protocol Therapy Per IRF AssessmentTime frame: From first dose of study drug up to Cycle 2 Day 25 (Each Cycle length=28 days)
  6. Phase 2: Percentage of Participants Who Achieved a Partial Remission (PR) Per IRF Assessment Per IWG Criteria at EOT VisitTime frame: At EOT visit 30 days after the last dose of study drug (at Month 7)
  7. Phase 2: Percentage of Participants Who Achieved an Overall Response Rate (ORR) Per IRF Assessment Per IWG Criteria at EOT VisitTime frame: At EOT visit 30 days after the last dose of study drug (at Month 7)
  8. Phase 2: Percentage of Participants Who Were Able to Complete 6 Cycles of Protocol Therapy at the Recommended DoseTime frame: From first dose of study drug up to Cycle 6 (Each Cycle length=28 days)

Locations

14 sites in 4 countries. Site status is shown where the registry gives one.

  • Children's Hospital Colorado

    Aurora, Colorado

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Jardim das Americas

    Paranã, Brazil

  • INCA - Instituto Nacional de Cancer

    Rio de Janeiro, Brazil

  • GRAACC - Grupo de Apoio ao Adolescente e a Crianca com Cancer

    São Paulo, Brazil

  • ICr - Instituto da Crianca - HCFMUSP

    São Paulo, Brazil

  • Hospital Santa Marcelina

    São Paulo, Brazil

  • Hospital Sao Rafael S/A

    Salvador, Estado de Bahia, Brazil

  • Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer

    Florence, Italy

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy

  • Ospedale Pediatrico Bambino Gesu,UOC Onco-ematologia

    Roma, Italy

  • Azienda Ospedaliera Citta della Salute e della Scienza di Torino

    Torino, Italy

  • NHO Nagoya Medical Center

    Nagoya, Aichi-ken, Japan

  • St. Marianna University School of Medicine Hospital

    Kawasaki-shi, Kanagawa, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.